Today: 13 March 2026
Subscribe

Marcin Frąckiewicz

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

IBM Slashes Thousands of Jobs Amid AI Boom – Why Big Blue Is Cutting Staff Now

IBM Slashes Thousands of Jobs Amid AI Boom – Why Big Blue Is Cutting Staff Now

IBM will lay off a “low single-digit percentage” of its global workforce in Q4 2025, affecting thousands of jobs. The company says the cuts support a shift toward AI and software, with most reductions expected outside the U.S. IBM stock dipped 1–2% after the announcement, following a 30% rise earlier in the year. Roles in AI research, marketing, and cloud engineering are among those impacted.
5 November 2025
·
Stocks Skyrocket to Record Highs as Fed Set to Cut Rates Again

Fed’s $50 Billion Repo Bailout: Credit Crunch Canary or Just Month-End Jitters?

The Federal Reserve injected $50 billion into the banking system on October 31, the largest liquidity boost since 2020, after overnight lending rates spiked above target. Banks tapped the Fed’s Standing Repo Facility in record amounts amid a month-end cash squeeze. The Fed halted quantitative tightening and will stop shrinking its balance sheet December 1. Analysts remain divided on whether the episode signals deeper financial stress.
5 November 2025
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Novo Nordisk cut its 2025 sales and profit outlook for the fourth time this year after third-quarter results missed forecasts, with Wegovy revenues below expectations. Operating profit fell 30% due to restructuring costs. The company faces rising competition from Eli Lilly and U.S. copycat drugs, as well as mounting pricing pressure. Shares have dropped up to 50% in 2025; Novo plans 9,000 job cuts and a $10 billion bid for Metsera.
5 November 2025
···
Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings

Stocks Plunge on AI Bubble Fears as Wall Street Warns of a 20% Correction

The Nasdaq fell over 2% Tuesday, marking the sharpest U.S. stock drop in nearly a month as tech shares tumbled. Wall Street CEOs warned of a likely correction, fueling a global sell-off that sent Japan’s Nikkei down nearly 5% and South Korea’s Kospi off 6% at one point. Bitcoin also slid below $100,000 amid the broader retreat from risk. Uncertainty over Federal Reserve policy and a prolonged U.S. government shutdown added to market jitters.
5 November 2025
········
Zeta Global (ZETA) – 17th Straight Beat & Raise Quarter Ignites AI-Cloud Rally – Analysts Eye ~$28 Target (≈+70% Upside)

Zeta Global (ZETA) – 17th Straight Beat & Raise Quarter Ignites AI-Cloud Rally – Analysts Eye ~$28 Target (≈+70% Upside)

Zeta (NYSE: ZETA) closed Nov. 4, 2025 at $16.70, down 5.2%, with after-hours trading near $18.06. Q3 revenue rose 26% year-over-year to $337.4 million, with net cash from operations up 68%. The company raised its FY2025 revenue outlook to $1.273–1.276 billion. Analyst consensus rates ZETA a “Strong Buy,” with an average 12-month price target of $28.
4 November 2025
··
Rivian Slashes 600 Jobs as EV Demand Slumps – Stock Hits & Experts Sound Alarm

Rivian Rally or Risk? EV Start-up Stock Jumps on Q3 Beat, Layoffs & R2 Hype

Rivian reported Q3 2025 revenue of $1.56 billion, up 78% year-over-year, and delivered 13,201 vehicles, its highest quarterly total. The company turned a positive adjusted gross profit of $24 million and reaffirmed 2025 delivery guidance at 41,500–43,500 vehicles. Shares closed at $12.98 on Nov. 4, down 5.2%, with a market cap near $15.2 billion. Rivian announced 600 layoffs in October to cut costs.
4 November 2025
···
Is ALAR Stock the Next AI Goldmine? Discover Alarum’s Explosive Run and What Analysts Are Saying

Is ALAR Stock the Next AI Goldmine? Discover Alarum’s Explosive Run and What Analysts Are Saying

Alarum Technologies (NYSE: ALAR) closed at $16.25 on Nov. 3, up roughly 55% year-to-date and about 150% in the past six months. Q2 2025 revenue reached $8.8 million with net profit at $0.3 million. The company forecasts Q3 revenue of $12.8 million, boosted by a new $3 million AI-data contract. Analyst consensus is bullish, with targets averaging $22; shares trade above key moving averages.
4 November 2025
··
UPST Stock Rockets on AI Lending Growth – What’s Next?

UPST Stock Rockets on AI Lending Growth – What’s Next?

Upstart reported Q3 revenue of $277 million, up 71% year-over-year, and GAAP net income of $31.8 million after a loss last year. Loan originations reached $2.9 billion on 428,056 loans. Management guided Q4 revenue to $288 million and expects a modest GAAP profit. UPST closed at $46.20 on Nov. 4, down from the previous close of $47.50.
4 November 2025
·
Axon Stock Rockets 420% Overseas as Wall Street Targets $1,000 – Should You Buy the Dip?

Axon Enterprise Rockets Past Revenue Goals – But EPS Miss Sends Stock Reeling

Axon reported Q3 2025 revenue of $711 million, up 31% year-over-year, led by 41% growth in Software & Services sales. The company posted a GAAP net loss of $2 million but non-GAAP net income of $98 million. Shares dropped about 14% after earnings, trading near $608, though the market cap remains around $56.9 billion. Management raised full-year revenue guidance to approximately $2.74 billion.
4 November 2025
··
Arista Networks (ANET) Stock Explodes on AI-Driven Growth – Will It Hit New Highs?

Arista Networks (ANET) Stock Soars on AI Data Center Boom – Analysts Weigh In

Arista Networks shares closed near $153 on Nov 4, 2025, down 2.8% after nearly doubling in six months. Q3 revenue rose 27.5% year-over-year to $2.3 billion, with non-GAAP EPS up 25%. The company launched 800GbE routers and acquired Broadcom’s VeloCloud SD-WAN. Analysts’ 12-month price targets range from $140 to $185, with most rating the stock a “Moderate Buy.”
4 November 2025
···
Supermicro Stock Plunges After AI-Driven Earnings Miss – Analysts Split on Next Move

Supermicro Stock Plunges After AI-Driven Earnings Miss – Analysts Split on Next Move

SMCI shares fell about 6% to $47–48 on Nov. 4 after Q1 FY2026 sales and earnings missed estimates, with revenue down 15.5% year-over-year. Management guided Q2 revenue to $10–11 billion, far above consensus. Analysts remain mixed, with most rating the stock Hold and an average target near $47.6. SMCI faces rising competition from Dell and HPE as AI server demand surges.
4 November 2025
··
AMD Stock Skyrockets on AI Mega-Deal – Latest Price, Q3 Earnings Preview & Expert Analysis

AMD Stock Forecast 2025: Will AI Deals Power More Gains or Is It Priced to Perfection?

AMD traded near $250 per share in early November 2025, with a market cap around $400 billion, up 60% year-over-year. Wall Street rates the stock a consensus “Buy,” but the average price target sits below current levels at $218. Major AI chip deals with OpenAI and Oracle have fueled record highs and rapid growth in data-center revenue. AMD’s valuation remains well above industry norms, raising risk if growth falters.
4 November 2025
···
Plug Power Stock Skyrockets on Hydrogen Hype – Will PLUG Keep Soaring? (Nov 2025 Update)

Plug Power Stock Forecast: Will PLUG Soar or Slip by End of 2025?

Plug Power shares trade near $2.70, valuing the company at about $2.9 billion. The stock remains volatile, up roughly 25–30% year-to-date but well below its 52-week high. Plug is unprofitable, posting a $227 million net loss last quarter, with Wall Street expecting losses through at least 2026. Analyst sentiment is mixed, with most rating it Hold and price targets clustered around current levels.
4 November 2025
·
UAMY Stock Skyrockets on $245M Pentagon Deal – Bubble or Buy?

UAMY Stock Forecast: Will U.S. Antimony’s Critical Mineral Boom Last Through 2025?

United States Antimony (UAMY) shares closed near $7.04 in early November after spiking to $19.71 in October, marking extreme volatility. Market cap stands at about $950 million. Q2 2025 revenue rose 160% to $17.5 million, with net income turning positive at $728,000. Analysts rate the stock a strong buy, but the average 12-month price target is $4.40, below the current price.
4 November 2025
···
Beyond Meat (BYND) Stock Forecast 2025: Will Plant-Based Meat Sizzle or Fizzle?

Beyond Meat (BYND) Stock Forecast 2025: Will Plant-Based Meat Sizzle or Fizzle?

Beyond Meat shares trade near $1.3 after plunging 99% from 2019 highs, with a brief late-October spike during a meme-stock rally. Wall Street analysts remain bearish, with no “Buy” ratings and an average price target of $2. The company faces shrinking sales, ongoing losses, and delayed Q3 earnings amid a sector-wide slump in plant-based meat demand. Recent debt-for-equity swaps and layoffs aim to keep the business afloat.
4 November 2025
·
Alien Probe or Cosmic Relic? Interstellar Comet 3I/ATLAS Baffles Scientists (updated 27.10.2025)

Third Interstellar Comet 3I/ATLAS Stuns Scientists With Surprising Brightening and Blue Glow

Comet 3I/ATLAS, discovered July 1, 2025, in Chile, is the third known interstellar object to enter the solar system. NASA says it poses no threat to Earth, staying at least 240 million km away. At perihelion on Oct. 29, it brightened rapidly and showed an unusual blue color, surprising astronomers. Telescopes worldwide, including Hubble and JWST, are tracking its progress.
4 November 2025
1 … 184 185 186 187 188 … 359

Stock Market Today

  • Edwards Lifesciences Stock Up 22.1% in a Year on TMTT Growth and Strategic Sales
    March 13, 2026, 9:50 AM EDT. Edwards Lifesciences (EW) surged 22.1% over the past year, vastly outperforming the industry's 3.8% decline while nearly matching the S&P 500's 23.5% rise. The company's Transcatheter Mitral and Tricuspid Therapies (TMTT) segment showed sustained growth, driven by global adoption of PASCAL and EVOQUE systems. EVOQUE gained Medicare coverage in March 2025, expanding its market. Its Transcatheter Aortic Valve Replacement (TAVR) platform exceeded $1 billion in sales for five straight quarters, benefiting from technological innovations and stable pricing. Edwards recently sold its Critical Care unit to Becton Dickinson for $4.2 billion to focus on heart therapies. The firm also advanced the CE-marked SAPIEN M3 and Alterra systems for mitral and congenital heart patients in Europe. Investors remain confident as Edwards scales fast-growing businesses and leverages clinical insights to retain a strong competitive position.
Go toTop